Financial Data and Key Metrics Changes - LifeMD reported a revenue growth of 25% year-over-year for 2025, totaling $194.1 million, with a gross margin of 85.7%, a slight decrease of 50 basis points compared to the previous year [21][22] - The fourth quarter revenue grew 4% year-over-year to $46.9 million, with a gross margin of 87.1%, an increase of 570 basis points from the prior year [19][20] - GAAP net income for the fourth quarter was $19 million or $0.41 per share, including a one-time benefit from the sale of WorkSimpli [20] - Adjusted EBITDA for the fourth quarter was $4.8 million, up from $1.1 million in the previous year [20] Business Line Data and Key Metrics Changes - The weight management business is experiencing record patient acquisition, with new signups approaching 700 per day, and customer acquisition costs have declined sequentially [4][19] - The men's health segment, represented by the Rex MD brand, has approximately 215,000 active patients and returned to growth in the second half of 2025 [8] - Women's health is a significant focus, with investments in launching this offering, including acquiring Optimal Human Health MD and partnerships with recognized experts in the field [5][6][7] Market Data and Key Metrics Changes - LifeMD has over 322,000 active subscribers and receives more than 120,000 unique daily visitors to its websites, indicating strong brand strength and demand for services [3] - The company expects to cover over 220 million lives through expanded partnerships with third-party benefits partners by the end of Q2 2026 [15] Company Strategy and Development Direction - LifeMD is focused on leveraging artificial intelligence to enhance care delivery, diagnostics, and patient operations, with plans to launch an AI clinical decision support tool in the first half of 2026 [11][12] - The company aims to build a comprehensive technology platform that integrates emerging AI capabilities and insurance benefits to improve patient experience [15][16] - LifeMD is committed to expanding its pharmacy operations, which are now licensed in all 50 states, to support personalized compounded medications [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, citing record demand in weight management and a diversifying specialty care platform [17] - The company anticipates returning to adjusted EBITDA profitability in Q2 2026 after making significant investments in patient acquisition [23] - Management highlighted the importance of insurance enablement in driving customer acquisition and retention, with expectations of improved metrics in this area [15][64] Other Important Information - LifeMD's balance sheet is strong, with nearly $37 million in cash and no debt, providing financial flexibility for growth investments [3][22] - The company is seeing high demand for the oral Wegovy pill, which has significantly contributed to new patient acquisitions in the weight management segment [27][71] Q&A Session Summary Question: Demand for Wegovy pill and brand products - Management noted strong demand for the Wegovy pill since its launch in January, with nearly doubled new patient acquisition in the weight loss business [27] Question: Revenue model for Wegovy pill - The pricing for the Wegovy pill is typically around $249 per month, with healthy gross margins of approximately $100 per order [30] Question: Investments in Q1 2026 - The company plans to increase sales and marketing expenditures significantly, with a focus on driving patient acquisition while reducing customer acquisition costs [33] Question: Revenue ramp and drivers - Growth will primarily come from subscriber count increases in the GLP-1 weight management business, women's health, and the Rex MD brand [36] Question: Women's health performance compared to other markets - Initial performance in women's health shows high intent and promising retention rates, with significant investments made in marketing and advisor partnerships [43][45] Question: Stickiness of Wegovy pill versus injectable - Retention rates for the Wegovy pill are better than the injectable, but long-term retention is still to be determined [54] Question: Comparison with competitors - LifeMD differentiates itself through its own provider group and a comprehensive care platform, offering synchronous care and a range of specialty services [56][58] Question: Patient acquisition channels - The marketing strategy remains similar to past efforts, with new partnerships yielding strong performance in patient acquisition [62] Question: Lifetime value of covered patients versus cash pay patients - Management believes that patients using insurance will have better retention and lifetime value compared to cash pay patients, though this is still being validated [64][67] Question: In-house pharmacy fulfillment - Approximately 70% of fulfillment is handled in-house, leading to a margin improvement of 150-200 basis points [72]

Core Insights - LifeMD, Inc. has sold its majority ownership interest in WorkSimpli Software LLC for an enterprise value of approximately $65 million, marking a strategic shift towards focusing on virtual healthcare and pharmacy services [1][4] - The transaction closed on November 4, 2025, with LifeMD receiving about $22 million in cash at closing, which is 91.6% of the base purchase price for the 80% interest sold [2][3] Financial Details - LifeMD is eligible to receive up to an additional $28 million in cash based on WorkSimpli achieving specific growth and operational targets over the next three years [3] - The initial investment by LifeMD in WorkSimpli was approximately $1.25 million, with a 73.3% ownership prior to the sale [4] Strategic Focus - Following the divestiture, LifeMD will concentrate on expanding its virtual care and pharmacy offerings, particularly in areas such as weight management, women's health, behavioral health, urgent care, and primary care [5] - LifeMD plans to broaden its platform into more complex cardiometabolic care offerings starting in the first half of 2026 [5] Leadership Commentary - LifeMD's CEO emphasized that the divestiture allows the company to sharpen its focus on building a comprehensive virtual care technology platform [4] - WorkSimpli's CEO expressed excitement about the independence gained from the transaction, which will enable further investment in their products and services [5]

Core Viewpoint - LifeMD, Inc. is facing a class action lawsuit due to alleged securities fraud, with a significant stock price drop following the company's revision of its revenue and EBITDA guidance for 2025 [2][3]. Group 1: Company Performance - On August 5, 2025, LifeMD announced a revision of its full-year 2025 guidance for revenue and adjusted EBITDA due to temporary challenges in its Rex MD business [2]. - Following this announcement, LifeMD's stock price fell by $5.31, or 44.8%, closing at $6.53 per share on August 6, 2025 [2]. Group 2: Allegations in the Lawsuit - The class action complaint alleges that LifeMD's management made materially false and misleading statements regarding the company's business and operations during the class period [3]. - Specific allegations include that the management overstated LifeMD's competitive position and failed to account for rising customer acquisition costs in its RexMD segment [3]. - The lawsuit claims that positive statements made by the management lacked a reasonable basis and were materially misleading [3]. Group 3: Legal Proceedings - Investors who purchased LifeMD securities during the class period are encouraged to file a lead plaintiff motion by October 27, 2025 [4]. - The law firm Glancy Prongay & Murray LLP is leading the class action and is available for inquiries regarding participation [5][6].